A Study to Investigate the Pharmacokinetics, Safety and Tolerability of CHF 5993 pMDI in Subjects With Renal Impairment.
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The study is performed to characterize the pharmacokinetics of glycopyrrolate bromide after
single administration of CHF 5993 pressurised Metered Dose Inhaler (pMDI) in subjects with
different level of renal impairment in comparison with matching healthy volunteers. Moreover,
the safety and tolerability of the study drug will be also evaluated.